PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Piccart-Gebhart, Martine J.
TI  - Lapatinib Plus Trastuzumab Was Not Superior to Trastuzumab Alone or Trastuzumab Followed by Lapatinib for Improved DFS in Women with HER2+ Breast Cancer
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 15--16
VI  - 14
IP  - 14
4099  - http://mdc.sagepub.com/content/14/14/15.short
4100  - http://mdc.sagepub.com/content/14/14/15.full
AB  - This article presents results of the global, Phase 3, randomized Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study; BIG 2–06/N063D [ALTTO; NCT00490139], conducted with more than 8300 women with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. This study evaluated concurrent or sequential adjuvant lapatinib plus trastuzumab. Although the combination is safe, the primary endpoint of improved disease-free survival was not met.